<DOC>
	<DOCNO>NCT01280201</DOCNO>
	<brief_summary>The incidence new diagnosed patient NET digestive tract include carcinoid pancreatic islet cell tumor range 2 10 per 100,000 western Countries ( Kulke M , Mayer R. N Engl J Med 340:858-868 , 1999 ) . Despite low incidence , prevalence tumor high relatively long survival estimate 35 % 5 year patient well moderate differentiate tumor ( Yao JC , et al . J Clin Oncol . 2008 ; 26:3063-3072 ) . In fact , digestive NETs second prevalent tumor derive digestive tract colorectal carcinoma . NETs characterize abundant vasculature , moreover VEGFR VEGFR overexpressed 60-84 % carcinoid pancreatic islet cell NETs ( Zhang et al . Cancer 2007 ; 109:1478-1486 ) . Other pro-angiogenic factor like platelet derive growth factor ( PDGFR ) also involved NET progression development ( Chaudhry A , et al.Cancer Res 1992 ; 52:1006-12 ) . Pazopanib oral tyrosine kinase inhibitor VEGFR , PDGFR KIT dual activity antiangiogenic also anti-tumoral agent ( Kumar et al . Mol Cancer Ther2007 ; 6:2012-2021 , Hurwitz et al . Clin Cancer Res 2009 ; 15:4220-4227 ) . Pazopanib seem good toxicity profile versus antiangiogenic tyrosine kinase inhibitor already show activity several tumor type like renal cell carcinoma ( Sternberg et al . J Clin Oncol 2009 ; 27 : abst . 5021 ) , soft tissue sarcoma ( Sleijfer et al . J Clin Oncol 2009 ; 27:3126-32 ) , hepatocellular carcinoma ( Yau et al . J Clin Oncol 2009 ; 27 : abst . 3561 ) , colorectal cancer ( Brady et al . J Clin Oncol 2009 ; 27 : abst.4133 ) , thyroid cancer ( Bible et al . J Clin Oncol 2009 ; 27 : abst . 3521 ) . The Spanish Group Research Neuroendocrine Tumors ( GETNE ) group active Member inside GENET group large tradition clinical trial NETs . The investigator hypothesize pazopanib may least good activity well safety profile VEGFR inhibitor progressive advanced metastatic NET tumor derive digestive tract .</brief_summary>
	<brief_title>Pazopanib Single Agent Advanced NETs</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<criteria>1 . Subjects must provide sign informed consent form prior performance studyspecific procedures assessment , must willing comply treatment follow‑up . Procedures conduct part subject 's clinical routine ( e.g. , blood count , image study ) obtain prior signing consent form might use screen baseline purpose provide procedure conduct specify protocol . 2 . Age ≥ 18 year . 3 . Diagnosis pancreatic islet cell tumor , well differentiate gastrointestinal NETs , pulmonary carcinoid well differentiate thymic carcinoid . Locallyadvanced metastatic disease document progressive CT scan , MRI , Octreoscan baseline within 12 month prior baseline . The previous scan use classify patient progressive disease baseline accord RECIST criterion . Octreoscan result may use document progressive disease baseline , RECIST determination study . 4 . ECOG performance status 01 . 5 . Disease amenable surgery , radiation combine modality therapy curative intent . 6 . Presence least one dimensionally measurable target lesion evaluation accord RECIST 1.0 criterion ( contrast enhance lesion large diameter &gt; 1cm , base CT MRI scan do within 4 week start treatment ) . 7 . Patients could receive treatment somatostatin analog , chemotherapy , antiVEGF , antimTOR agent previously entrance study final toxicity grade ≤ 1 . 8 . From patient sign inform consent form donate biological sample : Tumor tissue must provide available subject baseline serum sample collect baseline week 12 treatment biomarker analysis define biomarker section protocol . 9 . Adequate organ system function follow : 9.1.Hematologic system : Absolute neutrophil count ( ANC ) ≥ 1.5 X 10^9/L Hemoglobin ( 1 ) ≥ 9 g/dL ( 5.6 mmol/L ) Platelets ≥ 100 X 10^9/L Prothrombin time ( PT ) international normalize ratio ( INR ) ≤ 1.2 X upper limit normal ( ULN ) Partial thromboplastin time ( PTT ) ≤ 1.2 X ULN 9.2.Hepatic system ( 2 ) : Total bilirubin ≤ 1.5 X ULN AST ALT ≤ 2.5 X ULN 9.3.Renal system : Serum creatinine ≤ 1.5 mg/dL ( 133 µmol/L ) , Or , great 1.5 mg/dL : Calculated creatinine clearance ≥ 50 mL/min ( Note 1 ) : '' Subjects transfusion within 7 day screen assessment . '' ( Note 2 ) : `` Concomitant elevation bilirubin AST/ALT 1.0 x ULN permit '' 10 . A female eligible enter participate study : 10.1.Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) , include female : A hysterectomy A bilateral oophorectomy ( ovariectomy ) A bilateral tubal ligation Is postmenopausal 10.2.Childbearing potential , include female negative serum pregnancy test within 2 week prior first dose study treatment , preferably close first dose possible , agree use adequate contraception . GETNE acceptable contraceptive method , use consistently accordance product label instruction physician , follow : An intrauterine device document failure rate le 1 % per year . Vasectomized partner sterile prior female subject 's entry sole sexual partner female . Complete abstinence sexual intercourse 14 day exposure investigational product , dose period , least 21 day last dose investigational product . Doublebarrier contraception ( condom spermicidal jelly , foam suppository , film ; diaphragm spermicide ; male condom diaphragm spermicide ) . Oral contraceptive Female subject lactate discontinue nursing prior first dose study drug refrain nursing throughout treatment period 14 day follow last dose study drug . 11 . Life expectancy &gt; 3 month . 12 . Able swallow oral compound . 13 . Signed date informed consent document indicate patient inform pertinent aspect trial prior enrollment . 14 . Willingness ability comply schedule visit , treatment plan , laboratory test study procedure . 1 . Diagnosis second malignancy within last 5 year , except adequately treat basal cell squamous cell skin cancer , situ carcinoma cervix uterus . 2 . History clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis , except individual previouslytreated CNS metastasis , asymptomatic , requirement steroid antiseizure medication 6 month prior first dose study drug . Screening CNS image study ( compute tomography [ CT ] magnetic resonance image [ MRI ] ) require clinically indicated subject history CNS metastases . 3 . Clinically significant gastrointestinal abnormality may increase risk gastrointestinal bleeding include , limited : 3.1.Active peptic ulcer disease 3.2.Known intraluminal metastatic lesion/s risk bleed 3.3.Inflammatory bowel disease ( e.g . ulcerative colitis , Chrohn 's disease ) , gastrointestinal condition increase risk perforation 3.4.History abdominal fistula , gastrointestinal perforation , intra‑abdominal abscess within 28 day prior begin study treatment . 4 . Clinically significant gastrointestinal abnormality may affect absorption investigational product include , limited : 4.1.Malabsorption syndrome 4.2.Major resection stomach small bowel . 4.3.Active peptic ulcer disease 4.4.Known intraluminal metastatic lesion/s risk bleed 4.5.Inflammatory bowel disease ( e.g . ulcerative colitis , Chrohn 's disease ) , gastrointestinal condition increase risk perforation 4.6.History abdominal fistula , gastrointestinal perforation , intra‑abdominal abscess within 28 day prior begin study treatment . 5 . Presence uncontrolled infection . 6 . Corrected QT interval ( QTc ) &gt; 480 msec use Bazett 's formula . 7 . History one follow cardiovascular condition within past 6 month : 7.1.Cardiac angioplasty stenting 7.2.Myocardial infarction 7.3.Unstable angina 7.4.Coronary artery bypass graft surgery 7.5.Symptomatic peripheral vascular disease 7.6.Class III IV congestive heart failure , define New York Heart Association ( NYHA ) 8 . Poorly control hypertension [ define systolic blood pressure ( SBP ) ≥140 mmHg diastolic blood pressure ( DBP ) ≥ 90mmHg ] . 9 . History cerebrovascular accident include transient ischemic attack ( TIA ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . Note : Subjects recent DVT treat therapeutic anticoagulating agent least 6 week eligible . 10 . Prior major surgery trauma within 28 day prior first dose study drug and/or presence nonhealing wound , fracture , ulcer ( procedure catheter placement consider major ) . 11 . Evidence active bleeding bleed diathesis . 12 . Known endobronchial lesion and/or lesion infiltrate major pulmonary vessel . 13 . Hemoptysis excess 2.5ml within 8 week first dose study drug . 14 . Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedure . 15 . Unable unwilling discontinue use prohibit medication list Concomitant Medication Section least 14 day five halflives drug ( whichever longer ) prior first dose study drug duration study . 16 . Treatment follow anticancer therapy : radiation therapy , surgery tumor embolization within 28 day prior first dose pazopanib , chemotherapy , immunotherapy , biological therapy , investigational therapy hormonal therapy within 28 day prior first dose pazopanib . 17 . Any ongoing toxicity prior anticancer therapy &gt; Grade 1 and/or progress severity , except alopecia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Neuroendocrine Tumors</keyword>
	<keyword>Pazopanib</keyword>
	<keyword>GETNE</keyword>
	<keyword>Biomarkers</keyword>
</DOC>